Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?

World Psychiatry

Volumn 10, Issue 1, 2011, Pages 19-31

  Lawrie, Stephen M ^a   Olabi, Bayanne ^a   Hall, Jeremy ^a   Mcintosh, Andrew M ^a  

^a ROYAL EDINBURGH HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; Early diagnosis; Etiology; Likelihood ratio; Pathophysiology; Predictive power; Schizophrenia; Treatment response

Indexed keywords

BIOLOGICAL MARKER; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE;

ANAMNESIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DRUG RESPONSE; EARLY DIAGNOSIS; HUMAN; NEUROIMAGING; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SYMPTOM; SYSTEMATIC REVIEW;

EID: 79952369399     PISSN: 17238617     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2051-5545.2011.tb00004.x     Document Type: Review

References (153)

1. Kendell RE. The role of diagnosis in psychiatry. Oxford: Blackwell, 1975.
2. Kendell RE, Jablensky A. Distinguishing between the validity and utility of psychiatric diagnoses. Am J Psychiatry 2003;160:4-12. (Pubitemid 36042419)
3. Alarcon RD. Culture, cultural factors and psychiatric diagnosis: review and projections. World Psychiatry 2009;8: 131-9.
4. Fulford KW, Broome M, Stanghellini G et al. Looking with both eyes open: fact and value in psychiatric diagnosis? World Psychiatry 2005;4:78-86.
5. Kraepelin E. Lehrbuch der Psychiatrie. Leipzig: Barth, 1896.
6. Bleuler E. Dementia praecox, or the group of schizophrenias. New York: International University Press, 1911.
7. Cannon M, Jones P. Schizophrenia. J Neurol Neurosurg Psychiatry 1996;60: 604-13.
8. Murray RM, Jones PB, Susser E et al (eds). The epidemiology of schizophrenia. Cambridge: Cambridge University Press, 2002.
9. Lawrie SM, Johnstone EC, Weinberger DR. Schizophrenia: from neuroimaging to neuroscience. Oxford: Oxford University Press, 2004.
10. Gottesman II. Schizophrenia genesis: the origins of madness. New York: Freeman Press, 1991.
11. Hennekens CH, Buring JE. Epidemiology in medicine. New York: Little Brown, 1987.
12. Sackett DL, Haynes RB, Guyatt GH et al. Clinical epidemiology: a basic science for clinical medicine, 2nd ed. Boston: Little Brown, 1991
13. Sackett DL, Strauss SE, Richardson WS et al. Evidence-based medicine: how to practice and teach EBM. Edinburgh: Churchill Livingstone, 2000.
14. Lawrie SM, Mcintosh AM, Rao S. Critical appraisal for psychiatry. Edinburgh: Churchill Livingstone, 2000.
15. Kitchens JM. Does this patient have an alcohol problem? JAMA 1994;272:1782-7.
16. Holsinger T, Deveau J, Boustani M et al. Does this patient have dementia? JAMA 2007;297:2391-404.
17. Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed. New York: Academic Press, 1988.
18. Bell V, Halligan PW, Ellis HD. Diagnosing delusions: a review of inter-rater reliability. Schizophr Res 2006;86:76-9. (Pubitemid 44234065)
19. Goldman D, Hien DA, Haas GL et al. Bizarre delusions and DSM-III-R schizophrenia. Am J Psychiatry 1992;149:494-9.
20. Crichton P. First-rank symptoms or rank-and-file symptoms? Br J Psychiatry 1996;169:537-40.
21. Peralta V, Cuesta MJ. Diagnostic significance of Schneider's first-rank symptoms in schizophrenia. Comparative study between schizophrenic and non-schizophrenic psychotic disorders. Br J Psychiatry 1999;174:243-8. (Pubitemid 29147240)
22. Tandon R, Keshavan MS, Nasrallah HA Schizophrenia: "just the facts". What we know in 2008. 2. Epidemiology and etiology. Schizophr Res 2008;102:1-18.
23. Fogelson DL, Nuechterlein KH, Asamow RF et al. Validity of the family history method for diagnosing schizophrenia, schizophrenia-related psychoses, and schizophrenia-spectrum personality disorders in first-degree relatives of schizophrenia probands. Schizophr Res 2004; 68:309-17. (Pubitemid 38526152)
24. Goldstein JM, Buka SL, Seidman LJ et al. Specificity of familial transmission of schizophrenia psychosis spectrum and affective psychoses in the New England family study's high-risk design. Arch Gen Psychiatry 2010;67:458-67.
25. Geddes JR, Lawrie SM. Obstetric complications and schizophrenia: a meta-analysis. Br J Psychiatry 1995;167:786-93.
26. Cannon M, Jones PB, Murray RM. Obstetrical complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry 2002;159:1080-92. (Pubitemid 34743246)
27. Cantor-Graae E, Selten JP. Schizophrenia and migration: a meta-analysis and review. Am J Psychiatry 2005;162:12-24.
28. Semple DM, Mcintosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 2005;19:187-94. (Pubitemid 40577224)
29. Moore TH, Zammit S, Lingford-Hughes A et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-28. (Pubitemid 47094993)
30. Hall W, Degenhardt L. Cannabis use and the risk of developing a psychotic disorder. World Psychiatry 2008;7:68-71.
31. Tramèr MR, Carroll D, Campbell FA et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323:16-21.
32. Weinberg SM, Jenkins EA, Marazita ML et al. Minor physical anomalies in schizophrenia: a meta-analysis. Schizo- phr Res 2007;89:72-85. (Pubitemid 44881305)
33. Sommer I, Ramsey N, Kahn R et al. Handedness, language lateralisation and anatomical asymmetry in schizophrenia: meta-analysis. Br J Psychiatry 2001;178: 344-51. (Pubitemid 32280929)
34. Bramon E, Walshe M, McDonald C et al. Dermatoglyphics and schizophrenia: a meta-analysis and investigation of the impact of obstetric complications upon a-b ridge count. Schizophr Res 2005; 75:399-404.
35. Bombin I, Arango C, Buchanan RW. Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophr Bull 2005;31:962-77. (Pubitemid 41437791)
36. Chan RC, Xu T, Heinrichs RW et al. Neurological soft signs in schizophrenia: a meta-analysis. Schizophr Bull (in press).
37. Chan RC, Xu T, Heinrichs RW et al. Neurological soft signs in non-psychotic first-degree relatives of patients with schizophrenia: a systematic review and meta-analysis. Neurosci Biobehav Rev 2010;34:889-96.
38. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-45.
39. Mesholam-Gately RI, Giuliano AJ, Goff KP et al. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009;23:315-36.
40. Woodberry KA, Giuliano AJ, Seidman LJ. Premorbid IQ in schizophrenia: a meta-analytic review. Am J Psychiatry 2008;165:579-87.
41. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 2007; 64:532-42. (Pubitemid 46718286)
42. Aleman A, Hijman R, de Haan EH et al. Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 1999;156: 1358-66.
43. Forbes NF, Carrick LA, Mcintosh AM et al. Working memory in schizophrenia: a meta-analysis. Psychol Med 2009;39:889-905.
44. Henry JD, Crawford JR. A meta-analytic review of verbal fluency deficits in schizophrenia relative to other neurocognitive deficits. Cogn Neuropsychiatry 2005;10: 1-33. (Pubitemid 40460674)
45. Hoekert M, Kahn RS, Pijnenborg M et al. Impaired recognition and expression of emotional prosody in schizophrenia: review and meta-analysis. Schizophr Res 2007;96:135-45.
46. Bora E, Yucel M, Pantelis C. Theory of mind impairment in schizophrenia: meta-analysis. Schizophr Res 2009;109:1-9.
47. Reichenberg A, Weiser M, Rapp MA et al. Elaboration on premorbid intellectual performance in schizophrenia: intellectual decline and risk for schizophrenia. Arch Gen Psychiatry 2005;62:1297-304.
48. Kelly C, Sharkey V, Morrison G et al. Nithsdale Schizophrenia Surveys. 20. Cognitive function in a catchment-area-based population of patients with schizophrenia. Br J Psychiatry 2000;177: 348-53.
49. Al-Uzri MM, Reveley MA, Owen L et al. Measuring memory impairment in community-based patients with schizophrenia. Case-control study. Br J Psychiatry 2006;189:132-6. (Pubitemid 44231271)
50. Bora E, Yucel M, Pantelis C. Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond. Schizophr Bull 2010;36:36-42.
51. Stefanopoulou E, Manoharan A, Landau S et al. Cognitive functioning in patients with affective disorders and schizophrenia: a meta-analysis. Int Rev Psychiatry 2009;21:336-56.
52. Bora E, Yucel M, Pantelis C. Cognitive functioning in schizophrenia, schizo-affective disorder and affective psychoses: meta-analytic study. Br J Psychiatry 2009; 195:475-82.
53. Keefe RSE, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia? Biol Psychiatry 2005;57:688-91. (Pubitemid 40409709)
54. Keefe RS. Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry 2008; 7:22-8.
55. Keefe RS, Goldberg TE, Harvey PD et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004; 68:283-97.
56. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187-92. (Pubitemid 37494071)
57. Ng MY, Levinson DF, Faraone SV et al. Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol Psychiatry 2009;14:774-85.
58. Munafo MR, Atwood AS, Flint J. Neuregulin 1 genotype and schizophrenia. Schizophr Bull 2008;34:9-12.
59. O'Donovan MC, Craddock N, Norton N et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008;40:1053-5.
60. St. Clair D, Blackwood D, Muir W et al. Association within a family of a balanced autosomal translocation with major mental illness. Lancet 1990;336:13-9.
61. Bassett AS, Scherer SW, Brzustowicz LM. Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. Am J Psychiatry (in press).
62. Lakhan SE, Kramer A. Schizophrenia genomics and proteomics: are we any closer to biomarker discovery? Behav Brain Funct 2009;5:2.
63. Stober G, Ben-Shachar D, Cardon M et al. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry 2009; 10:127-55.
64. Taurines R, Dudley E, Grassl J et al. Proteomic research in psychiatry. J Psychopharmacol (in press).
65. Wiesmann M, Wandinger KP, Missler U et al. Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry 1999;45:1508-11. (Pubitemid 29457564)
66. Rothermundt M, Missler U, Arolt V et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 2001; 6:445-9. (Pubitemid 32566096)
67. Rothermundt M, Falkai P, Ponath G et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 2004;9:897-9.
68. Tan Y, Luo X, Yang F et al. Elevated serum S100B protein in first-episode drug-naive Chinese patients with schizophrenia. Schizophr Res (in press).
69. Potvin S, Stip E, Sepehry AA et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008;63:801-8. (Pubitemid 351410515)
70. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-57.
71. Zureick JL, Meltzer HY. Platelet MAO activity in hallucinating and paranoid schizophrenics: a review and meta-analysis. Biol Psychiatry 1988;24:63-78.
72. Heinrichs RW Meta-analysis and the science of schizophrenia: variant evidence or evidence of variants? Neurosci Biobehav Rev 2004;28:379-94.
73. Keshavan MS, Tandon R, Boutros NN et al. Schizophrenia, "just the facts": what we know in 2008. Part 3: neurobiology. Schizophr Res 2008;106:89-107.
74. Suddath RL, Christison GW, Torrey EF et al. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med 1990;322: 789-94. (Pubitemid 20094141)
75. Lawrie SM, Abukmeil SS. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br J Psychiatry 1998;172:110-20. (Pubitemid 28097708)
76. Wright IC, Rabe-Hesketh S, Woodruff PW et al. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry 2000;157:16-25. (Pubitemid 30027416)
77. Davidson L, Heinrichs RW. Quantification of brain imaging findings on the frontal and temporal lobes in schizophrenia: a meta-analysis. Psychiatry Res 2003;122: 69-87. (Pubitemid 36506475)
78. Lawrie SM, Mcintosh AM, Hall J et al. Brain structure and function changes during the development of schizophrenia: the evidence from studies of subjects at increased genetic risk. Schizophr Bull 2008;34:330-40. (Pubitemid 351323338)
79. Amone D, Cavanagh J, Gerber D et al. Magnetic resonance imaging studies in bipolar disorder and schizophrenia: meta-analysis. Br J Psychiatry 2009;195:194-201.
80. Ellison-Wright I, Bullmore E. Anatomy of bipolar disorder and schizophrenia: a meta-analysis. Schizophr Res 2010;117: 1-12.
81. Davatzikos C, Shen D, Gur RC et al. Whole-brain morphometric study of schizophrenia revealing a spatially complex set of focal abnormalities. Arch Gen Psychiatry 2005;62:1218-27. (Pubitemid 41586921)
82. Kawasaki Y, Suzuki M, Kherif F et al. Multivariate voxel-based morphometry successfully differentiates schizophrenia patients from healthy controls. Neuroimage 2007;34:235-42. (Pubitemid 44765235)
83. Takayanagi Y, Kawasaki Y, Nakamura K et al. Differentiation of first-episode schizophrenia patients from healthy controls using ROI-based multiple structural brain variables. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:10-7.
84. Pohl KM, Sabuncu MR. A unified framework for MR based disease classification. Inf Process Med Imaging 2009;21:300-13.
85. Zakzanis KK, Heinrichs RW. Schizophrenia and the frontal brain: a quantitative review. J Int Neuropsychol Soc 1999;5:556-66.
86. Glahn DC, Ragland JD, Abramoff A et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuro-imaging studies of working memory in schizophrenia. Hum Brain Mapp 2005; 25:60-9. (Pubitemid 40656193)
87. Achim AM, Lepage M. Episodic memory-related activation in schizophrenia: meta-analysis. Br J Psychiatry 2005;187:500-9.
88. McIntosh AM, Whalley HC, McKirdy J et al. Prefrontal function and activation in bipolar disorder and schizophrenia. Am J Psychiatry 2008;165:378-84. (Pubitemid 351704494)
89. Hall J, Whalley HC, Marwick K et al. Hippocampal function in schizophrenia and bipolar disorder. Psychol Med 2010; 40:761-70.
90. Calhoun V, Maciejewski P, Pearlson G et al. Temporal lobe and "default" hemodynamic brain modes discriminate between schizophrenia and bipolar disorder. Human Brain Mapp 2008;29:1265-75.
91. Shen H, Wang L, Liu Y et al. Discriminative analysis of resting-state functional connectivity patterns of schizophrenia using low dimensional embedding of fMRI. Neuroimage 2010;49:3110-21.
92. Yoon JH, Tamir D, Minzenberg MJ et al. Multivariate pattern analysis of functional magnetic resonance imaging data reveals deficits in distributed representations in schizophrenia. Biol Psychiatry 2008; 64:1035-41.
93. Zakzanis KK, Hansen KT. Dopamine D2 densities and the schizophrenic brain. Schizophr Res 1998;32:201-6.
94. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III - the final common pathway. Schizophr Bull 2009;35:549-62.
95. Bose SK, Turkheimer FE, Howes OD et al. Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr Res 2008;106:148-55.
96. Boutros NN, Arfken C, Galderisi S et al. The status of spectral EEG abnormality as a diagnostic test for schizophrenia. Schizophr Res 2008;99:225-37.
97. Bramon E, Rabe-Hesketh S, Sham P et al. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res 2004;70:315-29.
98. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 2005;76:1-23. (Pubitemid 40824557)
99. Kojima T, Matsushima E, Ohta K et al. Stability of exploratory eye movements as a marker of schizophrenia: a WHO multicenter study. Schizophr Res 2001;52:203-13.
100. Suzuki M, Takahashi S, Matsushima E et al. Exploratory eye movement dysfunction as a discriminator for schizophrenia: a large sample study using a newly developed digital computerized system. Eur Arch Psychiatry Clin Neurosci 2009; 259:186-94.
101. Poulton R, Caspi A, Moffitt TE et al. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry 2000;57:1053-8.
102. Weiser M, Reichenberg A, Rabinowitz J et al. Association between nonpsychotic psychiatric diagnoses in adolescent males and subsequent onset of schizophrenia. Arch Gen Psychiatry 2001;58:959-64. (Pubitemid 32937919)
103. Lewis G, David AS, Malmberg A et al. Non-psychotic psychiatric disorder and subsequent risk of schizophrenia. Cohort study. Br J Psychiatry 2000;177:416-20.
104. Klosterkötter J, Hellmich M, Steinmeyer EM et al. Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 2001;58:158-64. (Pubitemid 32142753)
105. Yung AR, Phillips LJ, Yuen HP et al. Risk factors for psychosis in an ultra high-risk group: psychopathology and clilnical features. Schizophr Res 2004;67:131-42. (Pubitemid 38251443)
106. Ott SL, Allen J, Erlenmeyer-Kimling L. The New York High-Risk Project: observations on the rating of early manifestations of schizophrenia. Am J Med Genet 2001;105:25-7.
107. Ruhrmann S, Schultze-Lutter F, Salokangas RK et al. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European Prediction Of Psychosis study. Arch Gen Psychiatry 2010;67:241-51.
108. Niemi LT, Suvisaari JM, Tuulio-Henriksson A et al. Childhood developmental abnormalities in schizophrenia: evidence from high-risk studies. Schizophr Res 2003;60: 239-58. (Pubitemid 36184713)
109. Johnstone EC, Ebmeier KP, Miller P et al. Predicting schizophrenia: findings from the Edinburgh high-risk study. Br J Psychiatry 2005;186:18-25. (Pubitemid 40070539)
110. Tarbox SI, Pogue-Geile MF. Development of social functioning in preschizophrenia children and adolescents: a systematic review. Psychol Bull 2008;134:561-83.
111. Erlenmeyer-Kimling L, Rock D, Roberts SA et al. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project Am J Psychiatry 2000; 157:1416-22.
112. Michie PT, Kent A, Stienstra R et al. Phenotypic markers as risk factors in schizophrenia: neurocognitive functions. Aust N Z J Psychiatry 2000;34(Suppl): S74-85.
113. Lawrie SM, Byrne M, Miller P et al. Neurodevelopmental indices and the development of psychotic symptoms in subjects at high risk of schizophrenia. Br J Psychiatry 2001;178:524-30. (Pubitemid 32531745)
114. Whyte MC, Brett C, Harrison LK et al. Neuropsychological performance over time in people at high risk of developing schizophrenia and controls. Biol Psychiatry 2006;59:730-9.
115. Pukrop R, Klosterkötter J. Neurocognitive indicators of clinical high-risk states for psychosis: a critical review of the evidence. Neurotox Res (in press).
116. Cannon TD, Cadenhead K, Comblatt B et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008;65:28-37.
117. Hall J, Whalley HC, Job DE et al. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci 2006;9:1477-8. (Pubitemid 44862654)
118. Mcintosh AM, Baig BJ, Hall J et al. Relationship of catechol-O-methyl- transferase variants to brain structure and function in a population at high risk of psychosis. Biol Psychiatry 2007;61:1127-34.
119. Caspi A, Moffitt TE, Cannon M et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005;57:1117-27. (Pubitemid 40615773)
120. Pantelis C, Velakoulis D, McGorry PD et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003;361:281-8. (Pubitemid 36126187)
121. Borgwardt SJ, McGuire PK, Aston J et al. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res 2008;106:108-14.
122. Sun D, Phillips L, Velakoulis D et al. Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr Res 2009;108:85-92.
123. Job DE, Whalley HC, Johnstone EC et al. Grey matter changes over time in high risk subjects developing schizophrenia. NeuroImage 2005;25:1023-30.
124. Schobel SA, Lewandowski NM, Corcoran CM et al. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry 2009;66: 938-46.
125. Koutsouleris N, Meisenzahl EM, Davatzikos C. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry 2009;66:700-12.
126. Job DE, Whalley HC, Mcintosh AM et al. Grey matter changes can improve the prediction of schizophrenia in subjects at high risk. BMC Medicine 2006;4:29.
127. Smieskova R, Fusar-Poli P, Allen P et al. Neuroimaging predictors of transition to psychosis - A systematic review and meta-analysis. Neurosci Biobehav Rev (in press).
128. Harris JM, Moorhead TW, Miller P et al. Increased prefrontal gyrification in a large high-risk cohort characterizes those who develop schizophrenia and reflects abnormal prefrontal development. Biol Psychiatry 2007;62:722-9.
129. Robinson DG, Woemer MG, Alvir JM et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-9. (Pubitemid 29162974)
130. Perkins DO, Gu H, Boteva K et al. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162:1785-804. (Pubitemid 41428609)
131. Schennach-Wolff R, Seemüller FH, Mayr A et al. An early improvement threshold to predict response and remission in first-episode schizophrenia. Br J Psychiatry 2010;196:460-6.
132. Leucht S, Busch R, Kissling W et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007;68:352-60. (Pubitemid 46506798)
133. Derks EM, Fleischhacker WW, Boter H et al. Antipsychotic drug treatment in first-episode psychosis: should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse? J Clin Psychopharmacol 2010;30:176-80.
134. Gaebel W, Riesbeck M, von Wilmsdorff M et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol 2010;20:310-6.
135. Stone JM, Raffin M, Morrison P et al. The biological basis of antipsychotic response in schizophrenia. J Psychopharmacol 2010;24:953-64.
136. Bertolino A, Caforio G, Blasi G et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004; 161:1798-805. (Pubitemid 39314673)
137. Arranz MJ, Munro J, Sham P et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998;32:93-9. (Pubitemid 28364714)
138. Hwang R, Zai C, Tiwari A et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant Pharmacogenomics J 2010;10:200-18.
139. Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment a meta-analysis. Am J Psychiatry (in press).
140. Friedman L, Lys C, Schulz SC. The relationship of structural brain imaging parameters to antipsychotic treatment response: a review. J Psychiatry Neurosci 1992;17:42-54. (Pubitemid 23141089)
141. Lawrie SM, Ingle GT, Santosh CG et al Magnetic resonance imaging and single photon emission tomography in treatment-responsive and treatment-resistant schizophrenia. Br J Psychiatry 1995; 167:202-10. (Pubitemid 26194130)
142. Kapur S, Zipursky R, Jones C et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-20
143. Itil TM, Shapiro D, Schneider SJ et al. Computerized EEG as a predictor of drug response in treatment resistant schizophrenics. J Nerv Ment Dis 1981; 169:629-37. (Pubitemid 11017372)
144. Galderisi S, Mucci A, Mignone ML et al. CEEG mapping in drug-free schizophrenics. Differences from healthy subjects and changes induced by haloperidol treatment Schizophr Res 1991;6: 15-23.
145. Czobor P, Volavka J. Pretreatment EEG predicts short-term response to haloperidol treatment. Biol Psychiatry 1991; 30:927-42.
146. Czobor P, Volavka J. Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve. Psychiatry Res 1992;42: 129-44.
147. Galderisi S, Maj M, Mucci A et al. QEEG alpha 1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. Biol Psychiatry 1994;35:367-74. (Pubitemid 24118464)
148. Moore NC, Tucker KA, Brin FB et al. Positive symptoms of schizophrenia: response to haloperidol and remoxipride is associated with increased alpha EEG activity. Hum Psychopharmacol 1997; 12:75-80. (Pubitemid 27110298)
149. Kendell RE, Brockington IF. The identification of disease entities and the relationship between schizophrenic and affective psychoses. Br J Psychiatry 1980; 137:324-31. (Pubitemid 11243351)
150. Kendell RE. Diagnosis and classification of functional psychoses. Br Med Bull 1987;43:499-513.
151. Nierenberg AA, Feinstein AR. How to evaluate a diagnostic marker test. Lessons from the rise and fall of dexamethasone suppression test. JAMA 1988;259:1699-702.
152. Guo Y, DuBois Bowman F, Kilts C. Predicting the brain response to treatment using a Bayesian hierarchical model with application to a study of schizophrenia. Hum Brain Mapp 2008;29:1092-109.
153. Lin CC, Wang YC, Chen JY et al. Artificial neural network prediction of clozapine response with combined pharmacogenetic and clinical data Comput Methods Programs Biomed 2008;91:91-9.